“`html
09/09/2025 – 11:50 PM
VANCOUVER, B.C. – Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical firm in the clinical stage specializing in therapies for diseases with critical unmet needs, is set to participate in the Clusterbusters 20th Annual U.S. Patient Conference, scheduled for September 11-14, 2025, in Grapevine, Texas.
The Clusterbusters conference is a pivotal event for the cluster headache community, uniting patients, caregivers, healthcare professionals, and advocates for a weekend dedicated to education, support, and networking. Lobe Sciences’ involvement reaffirms its dedication to pioneering innovative treatments for chronic cluster headaches and other underserved medical conditions.
“For 25 years, Clusterbusters has spearheaded research and education on the use of psychedelics to treat cluster headache,” stated Bob Wold, Founder and Executive Director of Clusterbusters. “We welcome Lobe Sciences and Cynaptec Pharmaceuticals to our conference to share their work developing conjugated psilocin as a treatment for chronic cluster headache. This medicine has great potential to better manage debilitating cluster headaches, and we support their expedited pathway to bring patients relief as soon as possible.”
Dr. Fred D. Sancilio, Chairman and CEO of Lobe Sciences Ltd., will elaborate on the ongoing research conducted by its subsidiary, Cynaptec Pharmaceuticals, Inc. Cynaptec’s primary compound, L-130, Conjugated Psilocin™, is under investigation as a potential therapeutic intervention for chronic cluster headaches. This novel compound aims to address the limitations of current treatments by offering a more targeted and potentially effective solution.
Lobe Sciences recently announced a $6 million funding injection into Cynaptec Pharmaceuticals, accompanied by an investor option for an additional $20 million, earmarked for the completion of the US FDA submission for L-130. This financial backing underscores the confidence in L-130’s potential. Dr. Sancilio commented, “We’ve been collaborating with Clusterbusters’ leadership for over a year, and their invaluable insights into patient experiences with this debilitating condition have been instrumental. Our objective at this conference is to foster a stronger connection with patients, establishing a patient advocacy team to aid in designing meaningful clinical endpoints, informed by firsthand experience with the disease.” This patient-centric approach is crucial for developing therapies that truly address the needs of those suffering from cluster headaches.
Lobe Sciences representatives will be available at the conference to engage with patients interested in contributing to study designs and sharing their perspectives for future relevant research. The company’s proactive engagement with the patient community reflects a growing trend in biopharmaceutical development, where patient input is increasingly valued for its ability to shape more effective and patient-friendly therapies.
About Conjugated Psilocin™ – Conjugated Psilocin™ is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, Conjugated Psilocin’s™ stability and bioavailability profile, and associated safety and efficacy signals, suggest potential for prescription drug development in a variety of neurological and psychiatric indications.
About Lobe Sciences Ltd.
Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:
• Cynaptec Pharmaceuticals, Inc. (a private Delaware company currently owned 64% by Lobe Sciences Ltd) is advancing Conjugated Psilocin (CP), a patented new chemical entity targeting Chronic Cluster Headache, for which it will seek an orphan indication. Substance use disorder (SUD) and possibly additional CNS disorders and other indications are under strategic review.
• Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.
Lobe’s pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.
FAQ
What is Lobe Sciences (LOBEF) presenting at the Clusterbusters 2025 conference?
Lobe Sciences will present research on L-130, Conjugated Psilocin™, their potential treatment for chronic cluster headaches at the conference in Grapevine, Texas.
How much funding has Lobe Sciences secured for Cynaptec Pharmaceuticals?
Lobe Sciences has secured $6 million in funding with an investor option for up to an additional $20 million to complete the US FDA submission of L-130.
When and where is the Clusterbusters 2025 conference taking place?
The Clusterbusters 20th Annual U.S. Patient Conference is taking place September 11-14, 2025, in Grapevine, Texas (near Dallas/Ft. Worth).
What is the purpose of LOBEF’s participation in the Clusterbusters conference?
Lobe Sciences aims to build connections with patients, establish a patient advocacy team, and gather input for designing meaningful clinical endpoints for their chronic cluster headache treatment studies.
Who is supporting Lobe Sciences’ research into cluster headache treatment?
Clusterbusters, the largest patient advocacy organization for cluster headache, has been working with Lobe Sciences for over a year, providing valuable patient experiences and supporting their treatment development.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/9022.html
